2023年第2版《NCCN胰腺癌临床实践指南》更新解读

doi:10.16139/j.1007-9610.2024.01.03

外科理论与实践 ›› 2024, Vol. 29 ›› Issue (01): 10-13.doi: 10.16139/j.1007-9610.2024.01.03

2023年第2版《NCCN胰腺癌临床实践指南》更新解读

陈佳浩, 姜翀弋()

复旦大学附属华东医院肝胆胰脾外科，上海 200040

收稿日期:2023-12-14 出版日期:2024-01-25 发布日期:2024-05-14
通讯作者: 姜翀弋 E-mail:jiangzhongyi9@126.com
基金资助:
国家自然科学基金(82372968);上海市申康医院发展中心项目(SHDC2024CRI080);复旦大学医学工程联合基金(XM03231533)

Interpretation of 2023 2nd NCCN clinical practice guidelines in oncology-pancreatic adenocarcinoma

CHEN Jiahao, JIANG Chongyi()

Department of Hepato-Biliary-Pancreatic & Splenic Surgery, Huadong Hospital, Fudan University, Shanghai 200040, China

Received:2023-12-14 Online:2024-01-25 Published:2024-05-14
Contact: JIANG Chongyi E-mail:jiangzhongyi9@126.com

摘要/Abstract

摘要：

胰腺癌是预后极差的消化系统恶性肿瘤。美国国立综合癌症网络（National Comprehensive Cancer Network, NCCN）结合最新高质量循证医学证据不断更新推出胰腺癌的临床实践指南以指导胰腺癌的规范化诊疗。2023年5月4日与6月19日《NCCN胰腺癌临床实践指南》分别进行了两次更新。相较于2022年第2版，这两次更新主要集中于最新的免疫/靶向治疗进展、NALIRIFOX方案的引入以及体能状态中等病人治疗方案的补充。本文结合相关循证医学证据对最新《NCCN胰腺癌临床实践指南》的更新进行解读。

关键词: 胰腺癌, 美国国立癌症综合网络(NCCN), 指南, 解读

Abstract:

Pancreatic adenocarcinoma, a severe digestive malignancy, is characterized by its poor prognosis. The National Comprehensive Cancer Network (NCCN) persistently refines its guidelines, integrating cutting-edge evidence-based medical insights to standardize the diagnostic and therapeutic strategies of pancreatic adenocarcinoma. The NCCN clinical practice guidelines in oncology-pancreatic adenocarcinoma were updated twice on May 4 and June 19, 2023, respectively. Compared to the 2022 predecessor, these two updates placed a particular emphasis on immunotherapy/targeted therapy, the introduction of NALIRIFOX regimen, and supplementary treatment protocols for patients with intermediate performance status. This article provided an interpretation of the latest updates to the NCCN clinical practice guidelines in oncology-pancreatic adenocarcinoma, integrating relevant evidence-based medical findings.

Key words: Pancreatic adenocarcinoma, National Comprehensive Cancer Network(NCCN), Guideline, Interpretation

中图分类号:

R735.9

陈佳浩, 姜翀弋. 2023年第2版《NCCN胰腺癌临床实践指南》更新解读[J]. 外科理论与实践, 2024, 29(01): 10-13.

CHEN Jiahao, JIANG Chongyi. Interpretation of 2023 2nd NCCN clinical practice guidelines in oncology-pancreatic adenocarcinoma[J]. Journal of Surgery Concepts & Practice, 2024, 29(01): 10-13.

参考文献 19

[1]	OZONO Y, KAWAKAMI H, UCHIYAMA N, et al. Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary-pancreatic cancers[J]. J Gastroenterol, 2023, 58(11):1081-1093. doi: 10.1007/s00535-023-02037-z pmid: 37698719
[2]	ASOKKUMAR R, YUNG KA C, LOH T, et al. Comparison of tissue and molecular yield between fine-needle biopsy (FNB) and fine-needle aspiration (FNA): a rando-mized study[J]. Endosc Int Open, 2019, 7(8):E955-E963.
[3]	KANDEL P, NASSAR A, GOMEZ V, et al. Comparison of endoscopic ultrasound-guided fine-needle biopsy versus fine-needle aspiration for genomic profiling and DNA yield in pancreatic cancer: a randomized crossover trial[J]. Endoscopy, 2021, 53(4):376-382.
[4]	NCCN Clinical Practice Guidelines in Oncology. Pancreatic adenocarcinoma (version 2.2023)[EB/OL].(2023-06-19)[2023-12-05]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455.
[5]	GKOLFAKIS P, CRINÒ S F, TZIATZIOS G, et al. Comparative diagnostic performance of end-cutting fine-needle biopsy needles for EUS tissue sampling of solid pancreatic masses: a network meta-analysis[J]. Gastrointest Endosc, 2022, 95(6):1067-1077.
[6]	COSTA B, VALE N. Dostarlimab: a review[J]. Biomo-lecules, 2022, 12(8):1031.
[7]	CERCEK A, LUMISH M, SINOPOLI J, et al. PD-1 bloc-kade in mismatch repair-deficient, locally advanced rectal cancer[J]. N Engl J Med, 2022, 386(25):2363-2376.
[8]	CHEN I M, JOHANSEN J S, THEILE S, et al. Rando-mized phase Ⅱ study of nivolumab with or without ipili-mumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC)[J]. J Clin Oncol, 2022, 40(27):3180-3189.
[9]	STRICKLER J H, SATAKE H, GEORGE T J, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer[J]. N Engl J Med, 2023, 388(1):33-43.
[10]	BEKAII-SAAB T S, YAEGER R, SPIRA A I, et al. Adagrasib in advanced solid tumors harboring a KRAS^G12C mutation[J]. J Clin Oncol, 2023, 41(25):4097-4106.
[11]	RAHMAN F A U, ALI S, SAIF M W. Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer[J]. Therap Adv Gastroenterol, 2017, 10(7):563-572. doi: 10.1177/1756283X17705328 pmid: 28804517
[12]	NCCN Clinical Practice Guidelines in Oncology. Pancreatic adenocarcinoma (version 2.2022)[EB/OL].(2022-12-06)[2023-12-05]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455.
[13]	WAINBERG Z A, MELISI D, MACARULLA T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial[J]. Lancet, 2023, 402(10409):1272-1281.
[14]	WAINBERG Z A, BEKAII-SAAB T, BOLAND P M, et al. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: a phase Ⅰ/Ⅱ study[J]. Eur J Cancer, 2021,151:14-24.
[15]	WANG-GILLAM A, LI C P, BODOKY G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial[J]. Lancet, 2016, 387(10018):545-557.
[16]	GHAZI R, ABIMANSOUR J P, MAHMOUD T, et al. Uncovered versus fully covered self-expandable metal stents for the management of distal malignant biliary obstruction[J]. Gastrointest Endosc, 2023, 98(4):577-584.
[17]	ALMADI M A, BARKUN A, MARTEL M. Plastic vs. self-expandable metal stents for palliation in malignant biliary obstruction: a series of meta-analyses[J]. Am J Gastroenterol, 2017, 112(2):260-273.
[18]	LI T T, SONG S L, XIAO L N, et al. Efficacy of fully co-vered self-expandable metal stents for the management of pancreatic duct strictures in chronic pancreatitis: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2020, 35(7):1099-1106.
[19]	SOFI A A, KHAN M A, AHMAD S, et al. Comparison of clinical outcomes of multiple plastic stents and covered metal stent in refractory pancreatic ductal strictures in chronic pancreatitis- a systematic review and meta-analysis[J]. Pancreatology, 2021, 21(5):854-861. doi: 10.1016/j.pan.2021.03.017 pmid: 33941467

2023年第2版《NCCN胰腺癌临床实践指南》更新解读

Interpretation of 2023 2nd NCCN clinical practice guidelines in oncology-pancreatic adenocarcinoma

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 19

相关文章 15

编辑推荐

Metrics

本文评价

[1]	中华医学会整形外科分会血管瘤脉管畸形学组. 血管瘤与脉管畸形诊疗指南（2024版） [J]. 组织工程与重建外科杂志, 2024, 20(1): 1-.
[2]	王美文, 傅宁稹, 王伟珅, 任新平. 胰十二指肠联合静脉切除重建术后早期血管栓塞的床旁超声诊断及危险因素分析[J]. 外科理论与实践, 2024, 29(01): 54-60.
[3]	齐中, 邢颖, 程石. 人工智能技术在当前生物学获益为主的胰腺癌诊疗模式中的发展方向[J]. 外科理论与实践, 2024, 29(01): 5-9.
[4]	陆忠晓, 汤杰, 黄文海. 以SEER为基础的列线图构建和胰腺癌病人生存预测[J]. 外科理论与实践, 2024, 29(01): 46-53.
[5]	韩亮, 刘昊楠, 仵正. 欧洲神经内分泌肿瘤学会：无功能胰腺神经内分泌肿瘤2023指南解读[J]. 外科理论与实践, 2024, 29(01): 14-26.
[6]	张太平, 翁桂湖, 刘悦泽. 可切除胰腺癌新辅助治疗的研究及指南解读，肯定还是否定?[J]. 外科理论与实践, 2024, 29(01): 1-4.
[7]	任加强, 武帅, 莫建涛, 周灿灿, 韩亮, 仵正. 磁性氧化铁纳米粒子应用于胰腺癌靶向诊疗的研究进展[J]. 外科理论与实践, 2024, 29(01): 61-66.
[8]	胡彬蔚, 沈柏用. 胰腺癌新辅助治疗的优势和进展[J]. 外科理论与实践, 2024, 29(01): 74-80.
[9]	许波进, 彭文芳, 黄珊. 2022版《中国甲状腺功能亢进症和其他原因所致甲状腺毒症诊治指南》解读[J]. 外科理论与实践, 2023, 28(06): 512-519.
[10]	严超, 陆晟, 燕敏, 朱正纲. 《日本胃癌治疗指南2021（第6版）》解读及瑞金实践[J]. 外科理论与实践, 2023, 28(04): 326-354.
[11]	郭晓倩, 姚玮艳. 透明质酸及其相关因子在胰腺癌方面的研究进展[J]. 内科理论与实践, 2023, 18(04): 305-308.
[12]	朱颖, 汤玉茗, 黄佳, 章永平, 姚玮艳. 全反式维A酸可促进肿瘤相关诱导配体对多种胰腺癌细胞的凋亡作用[J]. 内科理论与实践, 2023, 18(03): 171-176.
[13]	陶怡, 糜坚青. 2023年美国国立综合癌症网络（NCCN）《多发性骨髓瘤指南》（第2版）更新解读[J]. 诊断学理论与实践, 2023, 22(02): 121-126.
[14]	宋陆茜, 常春康. 2023年美国国立综合癌症网络（NCCN）《骨髓增生异常综合征临床实践指南》（第1版）解读[J]. 诊断学理论与实践, 2023, 22(02): 116-120.
[15]	丁玉芹, 石洪成, 季正标. 影像学检查在腹膜后肿瘤诊治中的应用及相关专家共识解读[J]. 外科理论与实践, 2022, 27(06): 511-516.